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Abstract 
Hepatitis C is an infectious disease affecting the liver, caused by the hepatitis C virus. The infection is often 
asymptomatic, but once established, chronic infection can progress to scarring of the liver (fibrosis), and 
advanced scarring (cirrhosis) which is generally apparent after many years.  The aim of our study are 
strengthening of surveys of the cases of Hepatitis C,  more knowledge of the causes leading to epidemics of 
hepatitis C,  also knowing the risk factors which caused delay in the treatment of patients in the acute phase,  
then  evaluate the number of persons who have the hepatitis C virus, finally molecular characterization and 
epidemiology of the isolated hepatitis C . In order to reach those goals  we carried out a survey of 1929 adult 
patients in the Department of virology at Central Laboratory of the Ministry of Health in Amman the capital of 
Jordan between january 2010 to December 2011 using a bioelisa HCV 4.0 is an immunoenzymatic .  Then total 
RNA have been  extracted from the recovered HCV using standard protocols. After that molecular epidemiology 
was performed using standard methods for PCR . Finally  detectable HCV RNA were submitted to  treatment 
follow using Real Time PCR.  a total of 1926 patients (1215 males, 711 females) were tested for anti-HCV 
antibodies, a total 149 patients were gave positive  results for anti-HCV antibodies, with an overall prevalence of  
9.%. The seroprevalence in males was approximately the double of that of females (66%  vs 48%). The most 
commonly caused of HCV infection was blood transfusion( 68%). Kidney dialysis ( 17%). Centre for addiction 
( 6%).  unknown cause (9%)Form  last results we conclude  that   the most cause of HCV is blood transfusion 
then Kidney dialysis.  
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Introduction 
Hepatitis C is an infection of the liver caused by the hepatitis C virus (HCV). )[1] It is difficult for the human 
immune system to eliminate the virus from the body, and infection with HCV usually becomes chronic. Over 
decades, chronic infection with HCV damages the liver and can cause liver failure in some people. )[1] 
The hepatitis C virus is transmitted by blood-to-blood contact. In developed countries, it is that 90% of persons 
with chronic HCV infection were infected through transfusion of unscreened blood or blood products or via 
injecting drug use or sexual exposure.[2] In developing countries, the primary sources of HCV infection are 
unsterilized injection equipment and infusion of inadequately screened blood and blood products.[3]Although 
injection drug use is the most common route of HCV infection, any practice, activity, or situation that involves 
blood-to-blood exposure can potentially be a source of HCV infection. [4]The virus may be sexually transmitted, 
although this is rare, and usually only occurs when an STD that causes open sores and bleeding is also present 
and makes blood contact more likely.[5] 
Methods: From January 2010 till June 2011, a total of 1926 individuals (1215 males and 711 females) Worked 
HCV test at Central Laboratory of the Ministry of Health in Amman . A second -generation Enzyme- Linked 
Immuno-Sorbent Assay (ELISA) test system using the commercial a bioelisa HCV 4.0 is an immunoenzymatic 
(Biokit)  kit, which was used to screen all patients  for antibodies to HCV. is an immunoenzymatic method in 
which the wells of a microplate are coated with recombinant antigens representing epitopes of HCV: Core, NS3, 
NS4 and NS5. Serum  samples are added to these wells. If antibodies specific for HCV are present in the sample, 
they will form stable complexes with the HCV antigens on the well. Excess sample is removed by a wash step 
and a rabbit anti-human IgG conjugated with peroxidase is then added and allowed to incubate. The conjugate 
will bind to any antigen-antibody complexes formed. After a second wash, a solution of enzyme substrate and 
chromogen is added. This solution will develop a blue colour if the sample is positive. The blue colour changes 
to yellow after blocking the reaction with sulphuric acid. The intensity of colour is proportional to anti-HCV 
antibodies concentration in the sample. Wells containing negative samples remain  
Colorless.  
Results of an assay are valid if the following criteria are accomplished:  
1. Substrate blank: absorbance value must be less than or equal to 0.100.  
Advances in Life Science and Technology                                                                                                 www.iiste.org 
ISSN 2224-7181 (Paper) ISSN 2225-062X (Online) 
Vol. 9, 2013 
 
2 
2. Negative control: absorbance value must be less than 0.100 after subtracting the blank.  
3. Low positive control: each individual absorbance value must not vary more than 30% over the mean of three 
replicates. The mean absorbance of low positive control must be higher than 0.200 after subtracting the blank.  
4. High positive control: absorbance must be higher than or equal to 0.800 after subtracting the blank.  
5. Ratio high positive control/Low positive control: must be higher than 2.5.  
6. Ratio negative control/Low positive control: must be lower than 0.5.  
A repeatedly positive result is indicative of HCV infection. The clinical history of the patient were taken in 
consideration.  Data were collected from the Central Laboratory  database. Samples of HCV positive serology. 
After that  total RNA have been  extracted from the recovered HCV using standard protocols and detectable 
HCV RNA were submitted to treatment follow using Real Time PCR. 
 
Results: A total of 1926 patients (1215 males, 711 females) were tested for anti-HCV antibodies, a total 149 
patients were gave positive  results for anti-HCV antibodies, with an overall prevalence of  92 %.table 1.  
 
Table  1.The number of anti-HCV  tests, number of abnormal  results and percentage  of positive results.  
%of abnormal results  N
O
 OF Abnormal 
results 
N
0
 of Test months 
9 22 233 January 
7 6 84 February 
9 20 222 March  
8 11 137 April  
8 12 156 May   
9 16 170 June 
4 8 193 July  
8 6 74 August  
7 11 150 September  
7 17 249 October  
8 8 103 November  
8 12 155 December  
9% 149 1926 Total  
 
 The seroprevalence in males was approximately the double of that of females (66%  vs 48%). The most 
commonly caused of HCV infection was blood transfusion( 68%). Kidney dialysis ( 17%). Centre for addiction 
( 6%).  unknown cause (9%). tables 2. 
 
Table.  2. The seroprevalence of male vs female and the most commonly caused of HCV infection 
Unknown 
cause 
Centre for 
addiction 
Kidney 
dialysis 
Blood 
transfusion 
Male N
O
 OF 
Abnormal 
results 
Female N
O
 
OF 
Abnormal 
results 
Months 
2 4 1 15 15 7 January 
1 0 2 3 4 2 February 
2 1 3 14 14 6 March 
2 0 2 7 8 3 April 
0 1 3 8 8 4 May 
1 1 4 10 9 7 June 
1 0 2 5 6 2 July 
1 0 1 4 4 2 August 
0 1 2 8 7 4 September 
2 1 4 10 10 7 October 
0 0 0 8 5 3 November 
1 0 2 9 9 3 December 
13 9 26 101 99 72 Total 
9% 6% 17% 68% 66% 48% Percentage  
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Discussion  
In a high-risk population (those with elevated ALTs or a risk factor such as history of injection drug use, 
multiple sexual partners, or blood transfusion before 1992), a reactive HCV EIA-2 or -3 is( enzyme 
immunoassay)  often sufficient to confirm HCV infection. [3]The next logical step would be either a qualitative 
HCV RNA PCR to differentiate acute versus chronic infection or a quantitative2 HCV RNA PCR. [2]The 
objective of this systematic review is to characterize hepatitis C virus (HCV) epidemiology in Jordan 
The reported prevalence of HCV infection  varies between 9% of  149 patients at Central Laboratory of the 
Ministry of Health in Amman  were found to have evidence of HCV infection, Blood transfusion seems to be the 
major route of infection. The reported prevalence of HCV infection in long-term dialysis patients varies between 
1-48% around the world, with higher rates being reported from areas where the incidence in general population 
is high. [10],[11]In Jordan,  the first study to be conducted among  dialysis population and showed a prevalence 
of 24.5%, a value similar to what has been reported in the neighboring countries in the Mediterranean basin. [12]
  
our study shows aprevalence of 17%.  
 
conclusion 
We note  that with the introduction of screening for HCV antibodies in blood donors, started in May 1994, a 
decline in the prevalence and incidence of HCV infection in our  population will occur. Finally our patients 
received interferon alpha and submitted to treatment follow using Real Time PCR. 
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